Fiche centre
McGill University Health Centre ( Site 0210)
Montreal — Canada
Essais liés2clinical trials
VilleMontreallocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03765918
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | ACTIVE_NOT_RECRUITING |
| Pembrolizumab 200 mg | Parkinson | Phase 3 | NCT03765918 | Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | ACTIVE_NOT_RECRUITING |